[When is it worth reducing overuse of health care services? The example of prescribing expensive antihypertensives].
Gandjour A, Lauterbach KW.
Med Klin (Munich). 2005 Sep 15. 100(9):535-41. PMID: 16170641
Adjunct Faculty
Karl W. Lauterbach
Adjunct Professor of Health Policy and Management
Health Policy and Management
Links
Bibliography
How much does it cost to change the behavior of health professionals? A mathematical model and an application to academic detailing.
Gandjour A, Lauterbach KW.
Med Decis Making. 2005 May-Jun. 25(3):341-7. PMID: 15951461
Does prevention save costs? Considering deferral of the expensive last year of life.
Gandjour A, Lauterbach KW.
J Health Econ. 2005 Jul. 24(4):715-24. PMID: 15960993
Technology assessment in dentistry: a comparison of the longevity and cost-effectiveness of inlays.
Gandjour A, Kerschbaum T, Reis A, Lauterbach KW.
Int J Technol Assess Health Care. 2005. 21(3):319-25. PMID: 16110711
[At what time is a reduction of medical under- or overtreatment sensible? Treatment of acute depression as an example].
Gandjour A, Lauterbach KW.
Psychiatr Prax. 2004 Apr. 31(3):157-62. PMID: 15042479
When is it worth introducing a quality improvement program? A mathematical model.
Gandjour A, Lauterbach KW.
Med Decis Making. 2003 Nov-Dec. 23(6):518-25. PMID: 14672112
Appropriateness of invasive cardiovascular interventions in German hospitals (2000-2001): an evaluation using the RAND appropriateness criteria.
Gandjour A, Neumann I, Lauterbach KW.
Eur J Cardiothorac Surg. 2003 Oct. 24(4):571-7; discussion 577-8. PMID: 14500076
Utilitarian theories reconsidered: common misconceptions, more recent developments, and health policy implications.
Gandjour A, Lauterbach KW.
Health Care Anal. 2003 Sep. 11(3):229-44. PMID: 14708935
An evidence-based disease-management program for patients with diabetic nephropathy.
Gandjour A, Lauterbach KW.
J Nephrol. 2003 Jul-Aug. 16(4):500-10. PMID: 14696751
Inductive reasoning in medicine: lessons from Carl Gustav Hempel's 'inductive-statistical' model.
Gandjour A, Lauterbach KW.
J Eval Clin Pract. 2003 May. 9(2):161-9. PMID: 12787179
News
From evidence to impact
Epidemiology—and turning research findings into policy—are both key to improving public health, says German health minister Karl Lauterbach at Cutter Lecture.
Preparing for the next pandemic
Karl Lauterbach, Germany’s federal minister of health, discussed the G7 Pact for Pandemic Readiness at a Harvard Chan School seminar.
Karl Lauterbach is Germany’s new health minister
Karl Lauterbach, an adjunct faculty member and alumnus of Harvard T.H. Chan School of Public Health, was sworn in as Germany’s health minister on December 8, 2021.
German model for drug price regulation may be good for U.S.
A five-year-old drug price regulatory system in Germany may be a good model for the U.S. to consider to tackle its own problem with unaffordable prescription drug prices, according to experts from Harvard T.H. Chan School of Public…